Income statement, balance sheet and cash flow statement for the last 5 fiscal years, taken from the XBRL data TFA Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2022
FY2022
FY2023
FY2024
FY2025
Revenue
0.88
0.05
0.88
1.25
1.25
Cost of revenue
1.06
0.01
0.12
0.35
0.48
Gross profit
-0.18
0.04
0.77
0.91
0.76
Research and development
0.03
0.12
General and administrative
0.09
0.34
0.54
Operating expenses
0.12
0.45
0.54
1.09
0.9
Operating income
-0.12
-0.42
0.23
-0.18
-0.14
Interest expense
0.01
0.07
0.03
Interest income
0
0
0
Other non-operating income
0
0
-0.04
-0.01
-0.01
Pre-tax income
-0.12
-0.42
0.19
-0.19
-0.15
Income tax
0
0
0.02
0.03
Income from continuing operations
-0.12
-0.42
0.17
-0.23
-0.15
Net income
-0.49
-0.72
0.75
-0.23
-0.15
EBITDA
0.03
-0.39
0.28
0.22
-0.01
EPS, basic
-4.91
-0.01
0.01
0.00
0.00
EPS, diluted
-4.91
-0.01
0.01
0.00
0.00
Shares, basic (weighted)
0.1
104
111
111
111
Shares, diluted (weighted)
0.1
104
111
111
111
Balance sheet
FY2022
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.1
0.01
0.02
0.04
0
Receivables
0.36
0.15
0
Inventory
0.48
0.31
0.67
Other current assets
0
0.06
0.1
Total current assets
1.13
0.5
0.33
0.6
1
Property, plant and equipment
1.71
0.08
2.81
3.91
3.63
Lease right-of-use assets
0.18
0.2
0.1
0.01
Other non-current assets
0.01
0.01
0.01
Total assets
3.26
2.1
3.35
4.62
4.66
Accounts payable
0.11
0.75
0.19
0.28
0.37
Accrued liabilities
0.06
0.06
0.03
0.03
0.09
Short-term debt
0.06
Total current liabilities
2.92
2.52
2.97
4.99
5.19
Long-term debt
0.41
0.41
0.43
Lease liabilities
0.2
0.12
0.11
0.01
Total liabilities
3.54
3.06
3.5
5
5.19
Total debt
0.47
0.43
Paid-in capital
0.22
0.22
0.22
0.22
Retained earnings
-0.5
-1.22
-0.47
-0.7
-0.85
Other comprehensive income
-0
0.04
0.09
0.09
0.09
Shareholders' equity
-0.28
-0.95
-0.15
-0.38
-0.53
Total equity
-0.28
-0.95
-0.15
-0.38
-0.53
Total liabilities and equity
3.26
2.1
3.35
4.62
4.66
Shares outstanding
111
111
111
111
111
Cash flow statement
FY2022
FY2022
FY2023
FY2024
FY2025
Net income
-0.49
-0.72
0.75
-0.23
-0.15
Depreciation and amortization
0.15
0.02
0.06
0.41
0.14
Deferred income tax
-0.04
Change in receivables
-0.35
0.19
Change in inventory
-0.17
0.05
-0.19
-0.36
Change in payables
0.11
-0.12
0.18
Cash from operations
-0.37
-0.32
0.36
0.31
-0.04
Capital expenditures
-0.1
-0
-0.32
-0.35
Cash from investing
-0.11
-0
-0.32
-0.31
Stock issued
0.23
Cash from financing
0.57
0.25
-0.03
Exchange rate effect
0
-0.01
-0
0.01
0
Net change in cash
0.1
-0.08
0.01
0.01
-0.03
Free cash flow
-0.47
-0.32
0.04
-0.04
Interest paid
0
0
Income taxes paid
0
0
0.02
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $9.18 on October 22, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
61.1%
Gross profit / revenue.
Operating margin
-11.3%
Operating income / revenue.
EBITDA margin
-0.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-12.4%
Pre-tax income / revenue.
Net margin
-12.4%
Net income / revenue.
Operating cash flow margin
-2.9%
Cash from operations / revenue.
Return on assets (ROA)
-3.3%
Net income / average total assets.
D&A / revenue
10.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-0.6%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
185.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-16.1%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
167.9%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EBITDA growth, 1y
-102.6%
EBITDA vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-111.5%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
0.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
30.3%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.1%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.19x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
$0.00
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.01
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
819x
Market cap / revenue.
EV/Sales
819x
Enterprise value / revenue.
Earnings yield
-0.0%
Net income / market cap (the inverse of P/E).
What was TFA Therapeutics, Inc.'s revenue in fiscal 2025?
TFA Therapeutics, Inc. reported revenue of $1.2M for fiscal 2025, 0.6% lower than the year before.
Was TFA Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $154.8K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.